Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.79 |
| ▸ | KIT | P10721 | 9/20 | 0.79 |
| ▸ | KDR | P35968 | 8/20 | 0.79 |
| ▸ | CSF1R | P07333 | 4/20 | 0.79 |
| ▸ | LCK | P06239 | 8/20 | 0.74 |
| ▸ | SRC | P12931 | 3/20 | 0.74 |
| ▸ | BRAF | P15056 | 2/20 | 0.68 |
| ▸ | BTK | Q06187 | 3/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949699 | 0.85 | MAPK14 (0.78) | MAPK14KITKDRCSF1RLCK | |
| SCHEMBL2952428 | 0.85 | LCK (1.00) | MAPK14KITKDRCSF1RLCK | |
| SCHEMBL2951773 | 0.84 | KDR (1.00) | MAPK14KITKDRCSF1RLCK | |
| SCHEMBL2944355 | 0.84 | KDR (0.79) | MAPK14KITKDRCSF1RLCK | |
| SCHEMBL2951430 | 0.83 | LCK (1.00) | MAPK14KITKDRCSF1RLCK | |
| SCHEMBL15987528 | 0.82 | KIT (0.72) | MAPK14KITKDRCSF1RLCK | |
| SCHEMBL2950585 | 0.82 | KDR (1.00) | MAPK14KITKDRCSF1RLCK | |
| SCHEMBL2950966 | 0.82 | KDR (1.00) | MAPK14KITKDRCSF1RLCK | |
| SCHEMBL1276318 | 0.81 | BRAF (1.00) | MAPK14KITKDRCSF1RLCK | |
| SCHEMBL3084639 | 0.81 | MAPK14 (0.71) | MAPK14KITKDRCSF1RLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | MAPK14 525/4885KIT 7/4885KDR 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.